Document is current
Any future updates will be listed below
-
Authors
Hoogeveen, Renate M.
Verweij, Simone L.
Kaiser, Yannick
Kroon, Jeffrey
Verberne, Hein J.
Vogt, Liffert
Moens, Sophie J. Bernelot
Stroes, Erik S. G.
-
Funding
Funding for this research was provided by:
Horizon 2020 (667837)
- License Information
-
More Information
Article History
Received: 15 December 2020
Accepted: 27 January 2021
First Online: 18 February 2021
Competing interests
: LV reports that his institution has received lecturing fees and advisory board fees from AstraZeneca, Ionis Pharmaceuticals, Pfizer Inc., SanofiGenzyme, Vifor Pharma. ES reports that his institution has received lecturing fees and advisory board fees from Amgen Inc., Regeneron, Sanofi, Akcea, Novartis and Athera. The other authors declare no competing interests.
